Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 5Completed 4Unknown 2Terminated 2Withdrawn 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 2Urinary Bladder Diseases 1Carcinoma in Situ 1

Interventions

Cyclophosphamide 240Radiotherapy 216Gemcitabine 187Cisplatin 185Carboplatin 182Docetaxel 166Bevacizumab 166Paclitaxel 144Rituximab 141Capecitabine 141pembrolizumab 139Oxaliplatin 124Nivolumab 124Dexamethasone 122Fluorouracil 113fludarabine 103Radiosurgery 101Doxorubicin 99fludarabine phosphate 96Irinotecan 96Etoposide 95Lenalidomide 93Cytarabine 91Magnetic Resonance Spectroscopy 90Radiation 89Leucovorin 88Filgrastim 88Bortezomib 86Cetuximab 80Pemetrexed 79

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × OTHER × Cystoscopy × Clear all
NCT02901548 2022-07-29

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
17 enrolled 9 charts
Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT02145390 2018-08-28

Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant Chemotherapy

University of Miami

Phase NA Terminated
1 enrolled 5 charts
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡